A Phase 2 interventional study of SB-705498 and FP in Rhinitis, sponsored by GlaxoSmithKline. Completed at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-13.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rhinitis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis · GlaxoSmithKline.
Among the 25 studies in Rhinitis by GlaxoSmithKline, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2011, is one of 8 in phase 2, and was the 8th registered.
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
Browse Rhinitis studies →None of the 25 studies in Rhinitis by GlaxoSmithKline is open now. The open studies under Rhinitis, anywhere →
Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 187 interventional studies indexed under Rhinitis.
Median enrollment 56 across the 21 interventional studies, 2,622 across the 4 observational. Of the 25 that completed or were terminated, 11 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Rhinitis by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject is eligible to participate if she is of:
Exclusion Criteria:
History of regular alcohol consumption within 6 months of the study defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental
Drug: SB-705498
Active Comparator
Drug: FP
Placebo Comparator
Drug: placebo
Experimental
Drug: SB-705498 · Drug: FP
Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8
Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Weighted mean (WM) of TNSS and its individual components (nasal congestion, rhinorrhoea, itching and sneezing) are presented on Day 8. Weighted mean was calculated over the time interval 0 to 4 hours after start of allergen chamber challenge by calculating the area under the curve of TNSS/component from time of the first observation to time of the last observation (AUC \[tf-t1 hours\]) using the trapezoidal rule, and then dividing by the actual relevant time interval (tf-t1) required by participant to complete the chamber challenge assessments. A Bayesian analysis was conducted to derive the posterior probability for TNSS.
Time frame: Day 8 of each treatment period
Mean TNSS and Its Individual Components From Day 4 to Day 8
Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Mean of TNSS and its individual components is presented pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge \[1 hour (hr)\] on Day 8.
Time frame: pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge [1 hour (hr)] on Day 8 of each treatment period
Total Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR)
Total Nasal Airflow is calculated as the sum of the left nostril and the right nostril airflow values. AAR is a very sensitive method of assessing clinical parameters of nasal obstruction (nasal flow, nasal resistance and nasal flow increase). A participant was instructed to breathe through one nostril while a sensor in the other nostril measured the difference in pre-nasal and choanal pressure. The system was connected to a computer. Nasal flow and nasal resistance were observed at pressure levels of 75, 150 and 300 Pascal. The defined measuring range for the flow was +-1000 milliliter per second (mL/s). Weighted means for total nasal airflow Resistance was calculated by dividing the area under the curve between 1 and 4 hours (via the linear trapezoidal method) by the total duration that the participant took to complete the chamber challenge assessments.
Time frame: Day 8
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo
The RQLQ composed of 28 items covering 7 domains of health. Each question is scored on a scale of 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). 7 domains were: Activities (3 items):1, 2, 3;Sleep (3 items): 4, 5, 6; Non-nose/eye symptoms (7 items): 7, 8, 9, 10, 11, 12, 13; Practical Problems (3 items): 14, 15, 16; Nasal Symptoms (4 items): 17, 18, 19, 20; Eye Symptoms (4 items): 21, 22, 23, 24; Emotional (4 items): 25, 26, 27, 28 consisted of total 28 items. Domain activity score = total post-baseline score for individualized activity items answered on both visits divided by total Baseline score for individualized activity items answered on both visits multiplied by the Baseline score for item(s) missing post-baseline. The global RQLQ score was calculated by averaging all 28 item scores, which ranges from 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). Higher scores indicate worsening of symptoms.
Time frame: Day 8
Area Under Concentration-time Curve (AUC) for SB-705498 on Day 8
Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.
Time frame: Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)
Maximum Observed Concentration (Cmax) for SB-705498 on Day 8
Plasma samples for pharmacokinetic analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as least squares geometric means with respective geometric coefficient of variation (% CV).
Time frame: Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)
Number of Participants With Vital Signs of Potential Clinical Importance (PCI)
Vital signs assessment included heart rate, blood pressure, and temperature. Criteria for vital sign values meeting potential clinical concern included: systolic blood pressure (SBP) \<85 and \>160 millimeters of mercury (mm Hg), diastolic blood pressure (DBP) \< 45 and \> 100 mm Hg, temperature \<36 and \>37.5 Degree Celsius and heart Rate \<40 and \>110 beats per minute. Only parameters with PCI values are reported.
Time frame: Up to Week 16
Change From Baseline in ECG Values: Heart Rate
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, and QTc intervals. Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.
Time frame: Baseline and Day 8 of each treatment period
Change From Baseline in ECG Values: PR Interval, QRS Duration, QT Interval, QTcB, QTcF
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, QTc corrected by Bazett's formula (QTcB) and QTc corrected by Fridericia's formula (QTcF). Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.
Time frame: Baseline and Day 8 of each treatment period
Number of Participants With Hematology Parameters of PCI
The PCC range for hematology parameters included white blood cell count, low: 0.67, high 1.82, neutrophil count, low: 0.83, Hemoglobin, male- high 1.03, female- high 1.13, hematocrit, male- high 1.02, female- high 1.17, Platelet Count, low: 0.67, high: 1.57, lymphocytes, low 0.81. Only parameters with PCI values are reported.
Time frame: Up to Week 16
Number of Participants With Clinical Biochemistry Parameters of PCI
The PCC range for clinical chemistry parameters included albumin, low: 0.86, millimole per liter (mmol)/L, calcium, low: 0.91, high: 1.06, glucose. Low: 0.71, high: 1.41, Potassium, low: 0.86, high: 1.10, Sodium, low: 0.96, high: 1.03, Total CO2, Low: 0.86, high: 1.14, Creatinine, in male, Low: \<75 micromole per liter (μmol/L), high: \>110 μmol/L, female, Low: \<65 μmol/L, high: \>95, Blood Urea Nitrogen (BUN), high: \>1.5xULN mmol/L, Uric Acid, in male, Low: \< 180 μmol/L, high: \> 480 μmol/L, female, Low: \< 120 μmol/L, high: \> 420. Only parameters with PCI values are reported.
Time frame: Up to Week 16
A total of 70 male and female participants with a history of allergic rhinitis (AR) were enrolled in this study. Study period was 14 April 2011 to 07 July 2011.
| Milestone | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 7 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 7 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 7 | 8 | 7 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 7 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 7 | 8 | 7 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 8 | 7 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Completed | 7 | 8 | 7 | 8 | 8 | 8 | 4 | 4 | 4 | 3 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Weighted mean (WM) of TNSS and its individual components (nasal congestion, rhinorrhoea, itching and sneezing) are presented on Day 8. Weighted mean was calculated over the time interval 0 to 4 hours after start of allergen chamber challenge by calculating the area under the curve of TNSS/component from time of the first observation to time of the last observation (AUC \[tf-t1 hours\]) using the trapezoidal rule, and then dividing by the actual relevant time interval (tf-t1) required by participant to complete the chamber challenge assessments. A Bayesian analysis was conducted to derive the posterior probability for TNSS.
| Score on scale | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| TNSS WM | 6.53 ± 2.300 | 3.65 ± 2.360 | 6.57 ± 2.418 | 4.14 ± 2.243 |
| Nasal congestion scoreWM | 1.80 ± 0.653 | 1.15 ± 0.792 | 1.82 ± 0.648 | 1.18 ± 0.715 |
| Rhinorrhoea score WM | 1.67 ± 0.693 | 0.94 ± 0.726 | 1.75 ± 0.697 | 1.05 ± 0.687 |
| Nasal itching score WM | 1.67 ± 0.760 | 0.94 ± 0.708 | 1.57 ± 0.886 | 1.17 ± 0.699 |
| Sneezing score WM | 1.39 ± 0.763 | 0.62 ± 0.573 | 1.43 ± 0.785 | 0.74 ± 0.560 |
Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Mean of TNSS and its individual components is presented pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge \[1 hour (hr)\] on Day 8.
| Score on a scale | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| TNSS,Day 4, pre-pm dose | 3.6 ± 2.47 | 2.4 ± 2.20 | 3.3 ± 2.65 | 2.6 ± 1.94 |
| TNSS,Day 5, pre-pm dose | 3.6 ± 2.58 | 2.0 ± 2.24 | 2.9 ± 2.60 | 2.3 ± 2.10 |
| TNSS,Day 6, pre-pm dose | 3.3 ± 2.45 | 1.8 ± 2.03 | 2.8 ± 2.74 | 2.0 ± 2.03 |
| TNSS,Day 7, pre-pm dose | 3.2 ± 2.26 | 1.7 ± 1.90 | 2.2 ± 2.37 | 1.9 ± 2.12 |
| TNSS,Day 8, pre-challenge (1hr) | 2.0 ± 1.88 | 1.3 ± 1.60 | 1.9 ± 1.52 | 1.1 ± 1.45 |
| Nasal congestion score code,Day 4, pre-pm dose | 1.0 ± 0.81 | 0.8 ± 0.69 | 0.9 ± 0.95 | 0.7 ± 0.65 |
| Nasal congestion score code,Day 5, pre-pm dose | 0.9 ± 0.82 | 0.7 ± 0.70 | 0.7 ± 0.88 | 0.6 ± 0.64 |
| Nasal congestion score code,Day 6, pre-pm dose | 0.9 ± 0.80 | 0.7 ± 0.74 | 0.8 ± 0.83 | 0.6 ± 0.68 |
| Nasal congestion score code,Day 7, pre-pm dose | 0.8 ± 0.69 | 0.6 ± 0.62 | 0.7 ± 0.82 | 0.6 ± 0.65 |
| Nasal congestion score code,Day 8, pre-challenge | 0.7 ± 0.67 | 0.6 ± 0.67 | 0.6 ± 0.59 | 0.4 ± 0.58 |
| Rhinorrhoea score code,Day 4, pre-pm dose | 0.9 ± 0.71 | 0.6 ± 0.76 | 0.9 ± 0.87 | 0.5 ± 0.65 |
| Rhinorrhoea score code,Day 5, pre-pm dose | 0.9 ± 0.75 | 0.5 ± 0.78 | 0.9 ± 0.90 | 0.5 ± 0.66 |
| Rhinorrhoea score code,Day 6, pre-pm dose | 0.8 ± 0.73 | 0.4 ± 0.65 | 0.8 ± 0.90 | 0.6 ± 0.62 |
| Rhinorrhoea score code,Day 7, pre-pm dose | 0.8 ± 0.65 | 0.4 ± 0.62 | 0.6 ± 0.78 | 0.4 ± 0.69 |
| Rhinorrhoea score code,Day 8, pre-challenge (1hr) | 0.6 ± 0.69 | 0.3 ± 0.59 | 0.6 ± 0.66 | 0.3 ± 0.50 |
| Nasal itching score code,Day 4, pre-pm dose | 0.9 ± 0.85 | 0.5 ± 0.66 | 0.7 ± 0.71 | 0.7 ± 0.71 |
| Nasal itching score code,Day 5, pre-pm dose | 0.8 ± 0.81 | 0.4 ± 0.63 | 0.4 ± 0.66 | 0.7 ± 0.75 |
| Nasal itching score code,Day 6, pre-pm dose | 0.8 ± 0.84 | 0.3 ± 0.58 | 0.5 ± 0.73 | 0.5 ± 0.72 |
| Nasal itching score code,Day 7, pre-pm dose | 0.8 ± 0.80 | 0.4 ± 0.62 | 0.3 ± 0.65 | 0.5 ± 0.72 |
| Nasal itching score code,Day 8, pre-challenge (1hr | 0.5 ± 0.65 | 0.3 ± 0.60 | 0.3 ± 0.49 | 0.3 ± 0.55 |
| Sneezing score code,Day 4, pre-pm dose | 0.9 ± 0.78 | 0.5 ± 0.68 | 0.9 ± 0.87 | 0.6 ± 0.68 |
| Sneezing score code,Day 5, pre-pm dose | 0.9 ± 0.85 | 0.4 ± 0.67 | 0.8 ± 0.83 | 0.4 ± 0.65 |
| Sneezing score code,Day 6, pre-pm dose | 0.8 ± 0.82 | 0.4 ± 0.57 | 0.7 ± 0.92 | 0.4 ± 0.68 |
| Sneezing score code,Day 7, pre-pm dose | 0.8 ± 0.75 | 0.3 ± 0.55 | 0.5 ± 0.73 | 0.4 ± 0.61 |
| Sneezing score code,Day 8, pre-challenge (1hr) | 0.3 ± 0.51 | 0.1 ± 0.26 | 0.4 ± 0.58 | 0.1 ± 0.31 |
Total Nasal Airflow is calculated as the sum of the left nostril and the right nostril airflow values. AAR is a very sensitive method of assessing clinical parameters of nasal obstruction (nasal flow, nasal resistance and nasal flow increase). A participant was instructed to breathe through one nostril while a sensor in the other nostril measured the difference in pre-nasal and choanal pressure. The system was connected to a computer. Nasal flow and nasal resistance were observed at pressure levels of 75, 150 and 300 Pascal. The defined measuring range for the flow was +-1000 milliliter per second (mL/s). Weighted means for total nasal airflow Resistance was calculated by dividing the area under the curve between 1 and 4 hours (via the linear trapezoidal method) by the total duration that the participant took to complete the chamber challenge assessments.
| Milliliters per second (mL/s) | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| Total Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR) | 306.99 ± 17.255 | 388.34 ± 17.207 | 299.68 ± 22.806 | 379.40 ± 18.783 |
The RQLQ composed of 28 items covering 7 domains of health. Each question is scored on a scale of 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). 7 domains were: Activities (3 items):1, 2, 3;Sleep (3 items): 4, 5, 6; Non-nose/eye symptoms (7 items): 7, 8, 9, 10, 11, 12, 13; Practical Problems (3 items): 14, 15, 16; Nasal Symptoms (4 items): 17, 18, 19, 20; Eye Symptoms (4 items): 21, 22, 23, 24; Emotional (4 items): 25, 26, 27, 28 consisted of total 28 items. Domain activity score = total post-baseline score for individualized activity items answered on both visits divided by total Baseline score for individualized activity items answered on both visits multiplied by the Baseline score for item(s) missing post-baseline. The global RQLQ score was calculated by averaging all 28 item scores, which ranges from 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). Higher scores indicate worsening of symptoms.
| Score on a scale | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo | 1.67 ± 0.119 | 0.99 ± 0.118 | 1.66 ± 0.177 | 1.14 ± 0.135 |
Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.
| nanograms*hour per mililiter (ng.h/mL) | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|
| Area Under Concentration-time Curve (AUC) for SB-705498 on Day 8 | 588.26 ± 71.4 | 608.84 ± 74.2 |
Plasma samples for pharmacokinetic analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as least squares geometric means with respective geometric coefficient of variation (% CV).
| nanograms per mililiter (ng/mL) | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|
| Maximum Observed Concentration (Cmax) for SB-705498 on Day 8 | 145.958 ± 68.8 | 154.231 ± 71.0 |
Vital signs assessment included heart rate, blood pressure, and temperature. Criteria for vital sign values meeting potential clinical concern included: systolic blood pressure (SBP) \<85 and \>160 millimeters of mercury (mm Hg), diastolic blood pressure (DBP) \< 45 and \> 100 mm Hg, temperature \<36 and \>37.5 Degree Celsius and heart Rate \<40 and \>110 beats per minute. Only parameters with PCI values are reported.
| Participants | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| Temperature,Low,period 3 | 2 | 0 | 0 | 0 |
| Temperature,Low,Follow up | 2 | 1 | 0 | 0 |
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, and QTc intervals. Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.
| beats per minute (bpm) | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| Change From Baseline in ECG Values: Heart Rate | -0.2 ± 11.32 | -4.7 ± 10.80 | -4.8 ± 8.09 | -2.6 ± 11.19 |
Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, QTc corrected by Bazett's formula (QTcB) and QTc corrected by Fridericia's formula (QTcF). Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.
| Milliseconds (msec) | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| PR Interval | 2.7 ± 8.31 | -1.2 ± 9.38 | 4.5 ± 9.29 | 0.4 ± 9.73 |
| QRS Duration | 0.8 ± 6.30 | 2.2 ± 5.52 | 0.8 ± 5.92 | -0.2 ± 5.05 |
| QT Interval | -1.5 ± 21.47 | 4.6 ± 22.12 | -0.3 ± 17.50 | 2.5 ± 17.93 |
| QTcB | -3.6 ± 17.30 | -9.3 ± 18.44 | -13.9 ± 20.79 | -4.1 ± 21.10 |
| QTcF | -2.9 ± 13.16 | -4.4 ± 13.37 | -9.0 ± 16.53 | -1.9 ± 13.33 |
The PCC range for hematology parameters included white blood cell count, low: 0.67, high 1.82, neutrophil count, low: 0.83, Hemoglobin, male- high 1.03, female- high 1.13, hematocrit, male- high 1.02, female- high 1.17, Platelet Count, low: 0.67, high: 1.57, lymphocytes, low 0.81. Only parameters with PCI values are reported.
| Participants | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| Total Neutrophils,low | 7 | 9 | 2 | 4 |
| Hematocrit,high | 0 | 0 | 1 | 0 |
| Hemoglobin,high | 0 | 0 | 1 | 0 |
The PCC range for clinical chemistry parameters included albumin, low: 0.86, millimole per liter (mmol)/L, calcium, low: 0.91, high: 1.06, glucose. Low: 0.71, high: 1.41, Potassium, low: 0.86, high: 1.10, Sodium, low: 0.96, high: 1.03, Total CO2, Low: 0.86, high: 1.14, Creatinine, in male, Low: \<75 micromole per liter (μmol/L), high: \>110 μmol/L, female, Low: \<65 μmol/L, high: \>95, Blood Urea Nitrogen (BUN), high: \>1.5xULN mmol/L, Uric Acid, in male, Low: \< 180 μmol/L, high: \> 480 μmol/L, female, Low: \< 120 μmol/L, high: \> 420. Only parameters with PCI values are reported.
| Participants | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| Creatinine,Low | 19 | 25 | 6 | 14 |
| Creatinine,High | 2 | 2 | 1 | 2 |
| Aspartate Amino Transferase,High | 1 | 1 | 1 | 0 |
| Potassium,High | 2 | 4 | 2 | 5 |
| Uric acid,High | 1 | 0 | 1 | 1 |
| Gamma Glutamyl Transferase,High | 1 | 1 | 2 | 1 |
| Total Bilirubin,High | 1 | 1 | 1 | 1 |
| Alanine Amino Transferase,High | 0 | 2 | 0 | 0 |
Collected over Non-SAEs and SAEs were collected from start of the treatment up to Week 16.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/68 (0%) | 0/68 (0%) | 24/68 (35.3%) |
| FP 200 μg | 0/69 (0%) | 0/69 (0%) | 28/69 (40.6%) |
| SB-705498 12 mg | 0/23 (0%) | 0/23 (0%) | 13/23 (56.5%) |
| SB-705498 + FP 12 mg | 0/47 (0%) | 0/47 (0%) | 19/47 (40.4%) |
| Event | Placebo | FP 200 μg | SB-705498 12 mg | SB-705498 + FP 12 mg |
|---|---|---|---|---|
| HypersensitivityImmune system disorders | 12/68 | 11/69 | 7/23 | 10/47 |
| HeadacheNervous system disorders | 9/68 | 11/69 | 5/23 | 5/47 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 3/68 | 2/69 | 0/23 | 0/47 |
| NasopharyngitisInfections and infestations | 1/68 | 1/69 | 1/23 | 1/47 |
| DiarrhoeaGastrointestinal disorders | 0/68 | 0/69 | 1/23 | 0/47 |
| VomitingGastrointestinal disorders | 0/68 | 0/69 | 1/23 | 0/47 |
| PyrexiaGeneral disorders | 0/68 | 1/69 | 1/23 | 0/47 |
| InfluenzaInfections and infestations | 0/68 | 2/69 | 0/23 | 1/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/68 | 0/69 | 0/23 | 1/47 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/68 | 0/69 | 0/23 | 1/47 |
All subjects population comprised of all participants who received at least one dose of study medication.
| Age, Continuous(Years) | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 29.6 ± 5.65 | 29.6 ± 9.24 | 28.0 ± 5.07 | 28.5 ± 9.20 | 28.5 ± 6.46 | 27.8 ± 6.34 | 24.5 ± 3.11 | 32.5 ± 10.54 | 25.3 ± 1.50 | 24.0 ± 1.00 | 28.3 ± 6.29 | 26.8 ± 11.03 | 28.1 ± 6.86 |
| Sex: Female, Male(Participants) | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 6 | 3 | 4 | 4 | 2 | 0 | 4 | 2 | 1 | 1 | 33 |
| Male | 3 | 6 | 2 | 5 | 4 | 4 | 2 | 4 | 0 | 1 | 3 | 3 | 37 |
| Race/Ethnicity, Customized(Participants) | Treatment A First, Then B, Then D | Treatment B First, Then A, Then D | Treatment B, Then D, Then A | Treatment A, Then D, Then B | Treatment D, Then A, Then B | Treatment D, Then B, Then A | Treatment A, Then B, Then C | Treatment B, Then A, Then C | Treatment B, Then C, Then A | Treatment A, Then C, Then B | Treatment C, Then A, Then B | Treatment C, Then B, Then A | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White(Wh)-Wh/Caucasian(Ca)/European(Eu)Heritage(H) | 7 | 8 | 8 | 7 | 7 | 7 | 4 | 4 | 4 | 3 | 4 | 4 | 67 |
| American Indian or Alaskan Native Wh-Wh/Ca/Eu H | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Wh - Arabic/North African H | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian - South East Asian H | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Apr 2011 to primary completion in Jul 2011, 2 months.
Results were first posted in Sep 2019, 8 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: SB 705498 · Fluticasone